FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to
December 08, 2013
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting
November 17, 2013
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis
November 25, 2013
RXi Pharmaceuticals’ Valuation Moves From Product To Platform
November 12, 2013
Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH
December 09, 2013
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme
December 11, 2013
from PR Newswire
Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris
December 03, 2013
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here